A Phase 1 interventional study of Tirzepatide and EE/NGM in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-27.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to look at how the body processes the commonly prescribed birth control pill, ethinylestradiol + norgestimate (EE/NGM), in healthy female participants and the effect of tirzepatide on how EE/NGM is processed by the body. Information about any side effects that may occur will also be collected.
Screening is required within 28 days prior to the start of the study. For each participant, the study will last about 20 weeks, including screening.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a 28-day packet of a combination oral contraceptive (OC) containing 21 days of tablets that consist of active ingredients (0.035 mg ethinyl estradiol (EE) and 0.25 mg norgestimate (NGM)) self-administered orally once-daily (QD) on Day 1 to Day 21, and 7 days of non-active tablets self-administer orally QD on Day 22 to Day 28 approximately the same time each day.
Drug: EE/NGM
Participants received a 28-day packet of a combination OC containing 21 days of tablets that consist of active ingredients (0.035 mg EE and 0.25 mg NGM) self-administered orally QD on Day 1 to Day 21, and 7 days of non-active tablets self-administer orally QD on Day 22 to Day 28 approximately the same time each day and a single dose 5 mg tirzepatide administered subcutaneously (SC).
Drug: Tirzepatide · Drug: EE/NGM
Administered SC
Also known as: LY3298176
Combination oral contraceptive administered orally
Period 1 and Period 2, Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) Within 1 Dosing Interval (AUC[0-tau]) of Ethinylestradiol (EE)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) Within 1 Dosing Interval (AUC\[0-tau\]) of Ethinylestradiol (EE)
Time frame: Period 1 and Period 2: Predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 48 hours postdose
Period 1 and Period 2, PK: Maximum Concentration (Cmax) of EE
PK: Cmax of EE
Time frame: Predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 48 hours postdose
Period 1 and Period 2, PK: Area Under the Concentration Versus Time Curve (AUC) Within 1 Dosing Interval (AUC[0-tau]) of Norelgestromin (NGMN)
PK: Area Under the Concentration Versus Time Curve (AUC) Within 1 Dosing Interval (AUC\[0-tau\]) of Norelgestromin (NGMN)
Time frame: Predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 48 hours postdose
Period 1 and Period 2, PK: Cmax of Norelgestromin (NGMN)
PK: Cmax of Norelgestromin (NGMN)
Time frame: Predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 48 hours postdose
| Milestone | Overall Study |
|---|---|
| Started | 40 |
| Received at least one dose of oc | 40 |
| Completed | 38 |
| Not completed | 2 |
| Withdrew: Adverse event | 1 |
| Withdrew: Protocol violation | 1 |
| Milestone | Overall Study |
|---|---|
| Started | 38 |
| Received at least one dose of oc | 38 |
| Completed | 37 |
| Not completed | 1 |
| Withdrew: Physician decision | 1 |
| Milestone | Overall Study |
|---|---|
| Started | 37 |
| Received at least one dose of oc | 37 |
| Received at least 1 dose of tirzepatide | 28 |
| Completed | 28 |
| Not completed | 9 |
| Withdrew: Adverse event | 5 |
| Withdrew: Dosing termination by sponsor | 4 |
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) Within 1 Dosing Interval (AUC\[0-tau\]) of Ethinylestradiol (EE)
| picogram hour per milliliter (pg*h/mL) | OC (0.035 mg EE and 0.25 mg NGM) | OC (0.035 mg EE and 0.25 mg NGM) + 5 mg Tirzepatide |
|---|---|---|
| Period 1 and Period 2, Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) Within 1 Dosing Interval (AUC[0-tau]) of Ethinylestradiol (EE) | 966 ± 40 | 811 ± 41 |
PK: Cmax of EE
| picogram per milliliter pg/mL | OC (0.035 mg EE and 0.25 mg NGM) | OC (0.035 mg EE and 0.25 mg NGM) + 5 mg Tirzepatide |
|---|---|---|
| Period 1 and Period 2, PK: Maximum Concentration (Cmax) of EE | 119 ± 33 | 49.6 ± 63 |
PK: Area Under the Concentration Versus Time Curve (AUC) Within 1 Dosing Interval (AUC\[0-tau\]) of Norelgestromin (NGMN)
| pg*h/mL | OC (0.035 mg EE and 0.25 mg NGM) | OC (0.035 mg EE and 0.25 mg NGM) + 5 mg Tirzepatide |
|---|---|---|
| Period 1 and Period 2, PK: Area Under the Concentration Versus Time Curve (AUC) Within 1 Dosing Interval (AUC[0-tau]) of Norelgestromin (NGMN) | 19900 ± 27 | 14600 ± 67 |
PK: Cmax of Norelgestromin (NGMN)
| pg/mL | OC (0.035 mg EE and 0.25 mg NGM) | OC (0.035 mg EE and 0.25 mg NGM) + 5 mg Tirzepatide |
|---|---|---|
| Period 1 and Period 2, PK: Cmax of Norelgestromin (NGMN) | 2070 ± 27 | 892 ± 74 |
Collected over Lead-In Up To 15 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lead-in: OC ( 0.035 mg EE and 0.25 mg NGM) | 0/40 (0%) | 0/40 (0%) | 9/40 (22.5%) |
| Period 1: OC ( 0.035 mg EE and 0.25 mg NGM) | 0/38 (0%) | 0/38 (0%) | 10/38 (26.3%) |
| Period 2: OC ( 0.035 mg EE and 0.25 mg NGM) + 5 mg Tirzepatide | 0/28 (0%) | 0/28 (0%) | 18/28 (64.3%) |
| Event | Lead-in: OC ( 0.035 mg EE and 0.25 mg NGM) | Period 1: OC ( 0.035 mg EE and 0.25 mg NGM) | Period 2: OC ( 0.035 mg EE and 0.25 mg NGM) + 5 mg Tirzepatide |
|---|---|---|---|
| NauseaGastrointestinal disorders | 4/40 | 1/38 | 11/28 |
| Decreased appetiteMetabolism and nutrition disorders | 2/40 | 1/38 | 6/28 |
| VomitingGastrointestinal disorders | 1/40 | 0/38 | 5/28 |
| HeadacheNervous system disorders | 1/40 | 4/38 | 5/28 |
| Abdominal discomfortGastrointestinal disorders | 2/40 | 1/38 | 4/28 |
| Abdominal painGastrointestinal disorders | 1/40 | 1/38 | 4/28 |
| Abdominal distensionGastrointestinal disorders | 2/40 | 0/38 | 3/28 |
| ChillsGeneral disorders | 0/40 | 0/38 | 3/28 |
| PainGeneral disorders | 0/40 | 0/38 | 3/28 |
| Corona virus infectionInfections and infestations | 0/40 | 0/38 | 2/28 |
All participants who received at least one dose of oral contraceptive or tirzepatide.
| Age, Continuous(years) | Overall Study |
|---|---|
| Mean | 33.6 ± 7.6 |
| Sex: Female, Male(Participants) | Overall Study |
|---|---|
| Female | 40 |
| Male | 0 |
| Ethnicity (NIH/OMB)(Participants) | Overall Study |
|---|---|
| Hispanic or Latino | 23 |
| Not Hispanic or Latino | 17 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Overall Study |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 18 |
| White | 20 |
| More than one race | 1 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Overall Study |
|---|---|
| United States | 40 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2020 to primary completion in Feb 2021, 11 months.
Results were first posted in Mar 2023, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide